Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: Implications for individual genome sequencing

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Bodian, Dale L ^a   McCutcheon, Justine N ^a,b   Kothiyal, Prachi ^a   Huddleston, Kathi C ^a   Iyer, Ramaswamy K ^a   Vockley, Joseph G ^a   Niederhuber, John E ^a  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b Life Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; ANCESTRY GROUP; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GERM LINE; HETEROZYGOTE; HUMAN; MALE; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PATHOGENICITY; PREVALENCE; PTEN GENE; SELF REPORT; SOMATIC MUTATION; TP53 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ADOLESCENT; ALLELE; CHEMICAL STRUCTURE; COHORT ANALYSIS; DNA SEQUENCE; GENE POOL; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HEALTH; HUMAN GENOME; MIDDLE AGED; NEOPLASM; OPEN READING FRAME; PHYLOGENY; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENE POOL; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GERM-LINE MUTATION; HEALTH; HUMANS; MALE; MIDDLE AGED; MODELS, MOLECULAR; NEOPLASMS; OPEN READING FRAMES; PHYLOGENY; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84899618905     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094554     Document Type: Article

References (84)

1. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, et al. (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115: 2222-2233.
2. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, et al. (2006) SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 34: D617-621.
3. Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, et al. (2012) Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 91: 97-108.
4. Neuhausen SL (1999) Ethnic differences in cancer risk resulting from genetic variation. Cancer 86: 2575-2582.
5. Bodmer W, Tomlinson I (2010) Rare genetic variants and the risk of cancer. Curr Opin Genet Dev 20: 262-267.
6. Ferretti C, Bruni L, Dangles-Marie V, Pecking AP, Bellet D (2007) Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update 13: 121-141.
7. Soundararajan R, Rao AJ (2004) Trophoblast 'pseudo-tumorigenesis': significance and contributory factors. Reprod Biol Endocrinol 2: 15.
8. Huddleston K, Glanowski S, Klein E, Wong WS (2013) Molecular Study of Preterm Birth: Genomic Ancestry, Race, and Ethnicity. Cleveland Clinic 9th Annual Nursing Research Conference. Warrensville Heights, Ohio.
9. Carnevali P, Baccash J, Halpern AL, Nazarenko I, Nilsen GB, et al. (2012) Computational techniques for human genome resequencing using mated gapped reads. J Comput Biol 19: 279-292.
10. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, et al. (2010) Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327: 78-81.
11. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921.
12. glu-genetics website. Available: http://code.google.com/p/glu-genetics/. Accessed 2012 April 2.
13. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, et al. (2013) The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res 41: D64-69.
14. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. (dbSNP Build ID: 137). Available: http://www.ncbi.nlm.nih.gov/SNP/.
15. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, et al. (2010) COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38: D652-657.
16. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249.
17. Liu X, Jian X, Boerwinkle E (2011) dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat 32: 894-899.
18. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164.
19. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, et al. (2009) The WEKA Data Mining Software: An Update. SIGKDD Explorations 11: 10-18.
20. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
21. Alexander DH, Novembre J, Lange K (2009) Fast model-based estimation of ancestry in unrelated individuals. Genome Res 19: 1655-1664.
22. Libiger O, Schork NJ (2012) A Method for Inferring an Individual's Genetic Ancestry and Degree of Admixture Associated with Six Major Continental Populations. Front Genet 3: 322.
23. Campbell I (2007) Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med 26: 3661-3675.
24. R Core Team (2013) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria. Available: http://www.R-project.org.
25. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, et al. (2011) The variant call format and VCFtools. Bioinformatics 27: 2156-2158.
26. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
27. Jmol: an open-source Java viewer for chemical structures in 3D. Available: http://www.jmol.org/. Accessed 2013 September 7.
28. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, et al. (2014) ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014 42:D980-5.
29. Ajay SS, Parker SC, Abaan HO, Fajardo KV, Margulies EH (2011) Accurate and comprehensive sequencing of personal genomes. Genome Res 21: 1498-1505.
30. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, et al. (2012) Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337: 64-69.
31. Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, et al. (2012) An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 337: 100-104.
32. Pritchard JK (2001) Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 69: 124-137.
33. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, et al. (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56-65.
34. Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, et al. (2012) Deleterious-and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am J Hum Genet 91: 1022-1032.
35. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, et al. (2003) The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 348: 1170-1175.
36. Gonzalez Burchard E, Borrell LN, Choudhry S, Naqvi M, Tsai HJ, et al. (2005) Latino populations: a unique opportunity for the study of race, genetics, and social environment in epidemiological research. Am J Public Health 95: 2161-2168.
37. Campbell MC, Tishkoff SA (2008) African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 9: 403-433.
38. Savas S, Schmidt S, Jarjanazi H, Ozcelik H (2006) Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: potential breast cancer risk alleles and their distribution across human populations. Hum Genomics 2: 287-296.
39. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, et al. (1994) Is p53 polymorphism maintained by natural selection? Hum Hered 44: 266-270.
40. Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, et al. (2003) Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res 9: 4396-4403.
41. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107.
42. Pilato B, Martinucci M, Danza K, Pinto R, Petriella D, et al. (2011) Mutations and polymorphic BRCA variants transmission in breast cancer familial members. Breast Cancer Res Treat 125: 651-657.
43. Chen J, Guo L, Peiffer DA, Zhou L, Chan OT, et al. (2008) Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues. Int J Cancer 122: 2249-2254.
44. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, et al. (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27: 4406-4412.
45. van Erp NP, Mathijssen RH, van der Veldt AA, Haanen JB, Reyners AK, et al. (2010) Myelosuppression by sunitinib is flt-3 genotype dependent. Br J Cancer 103: 757-758.
46. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, et al. (2013) Cancer genome landscapes. Science 339: 1546-1558.
47. Kurian AW (2010) BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 22: 72-78.
48. Ostrow KL, McGuire V, Whittemore AS, DiCioccio RA (2004) The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity. Cancer Genet Cytogenet 153: 177-180.
49. Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, et al. (2004) Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41: 492-507.
50. Coquelle N, Green R, Glover JN (2011) Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition. Biochemistry 50: 4579-4589.
51. Williams RS, Green R, Glover JN (2001) Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8: 838-842.
52. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, et al. (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45: 353-361, 361e351-352.
53. Chen X, Truong TT, Weaver J, Bove BA, Cattie K, et al. (2006) Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat 27: 427-435.
54. Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, et al. (2002) BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297: 1837-1848.
55. Guidugli L, Pankratz VS, Singh N, Thompson J, Erding CA, et al. (2013) A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Res 73: 265-275.
56. Olivier M, Petitjean A, Caron de Fromentel C, Hainaut P (2010) TP53 Mutation in Human Cancers: Selection versus Mutagenesis. In: Ayed A, Hupp T, editors. p53. Austin, Texas: Landes Bioscience. pp. 1-18.
57. Denisov EV, Cherdyntseva NV, Litviakov NV, Malinovskaya VA, Voevada MI (2012) TP53 Gene Polymorphisms in Cancer Risk: The Modulating Effect of Ageing, Ethnicity, and TP53 Somatic Abnormalities. In: Cheng Y, editor. Tumor Suppressor Genes: InTech. Available: http://www.intechopen.com/ books/tumor-suppressor- genes/tp53-gene-polymorphisms-in-cancer-risk-themodulating-effects-of-ageing- ethnicity-and-tp53-somatic-ab.
58. Keller G, Vogelsang H, Becker I, Plaschke S, Ott K, et al. (2004) Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet 41: e89.
59. Hancock JF, Paterson H, Marshall CJ (1990) A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63: 133-139.
60. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, et al. (1999) Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99: 323-334.
61. Keniry M, Parsons R (2008) The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27: 5477-5485.
62. Kilpivaara O, Aaltonen LA (2013) Diagnostic cancer genome sequencing and the contribution of germline variants. Science 339: 1559-1562.
63. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, et al. (eds) SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD. Available: http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
64. Fletcher O, Houlston RS (2010) Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 10: 353-361.
65. Anothaisintawee T, Teerawattananon Y, Wiratkapun C, Kasamesup V, Thakkinstian A (2012) Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat 133: 1-10.
66. Win AK, Macinnis RJ, Hopper JL, Jenkins MA (2012) Risk prediction models for colorectal cancer: a review. Cancer Epidemiol Biomarkers Prev 21: 398-410.
67. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, et al. (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98: 1457-1466.
68. Macinnis RJ, Antoniou AC, Eeles RA, Severi G, Al Olama AA, et al. (2011) A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol 35: 549-556.
69. Vazquez AI, de los Campos G, Klimentidis YC, Rosa GJ, Gianola D, et al. (2012) A comprehensive genetic approach for improving prediction of skin cancer risk in humans. Genetics 192: 1493-1502.
70. Quiles F, Fernandez-Rodriguez J, Mosca R, Feliubadalo L, Tornero E, et al. (2013) Functional and structural analysis of C-terminal BRCA1 missense variants. PLoS One 8: e61302.
71. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, et al. (2010) Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 28: 4029-4037.
72. Goldstein DB, Allen A, Keebler J, Margulies EH, Petrou S, et al. (2013) Sequencing studies in human genetics: design and interpretation. Nat Rev Genet 14: 460-470.
73. Cann HM, de Toma C, Cazes L, Legrand MF, Morel V, et al. (2002) A human genome diversity cell line panel. Science 296: 261-262.
74. Maples BK, Gravel S, Kenny EE, Bustamante CD (2013) RFMix: A Discriminative Modeling Approach for Rapid and Robust Local-Ancestry Inference. Am J Hum Genet 10.1016/j.ajhg.2013.06.020
75. Burke W, Matheny Antommaria AH, Bennett R, Botkin J, Clayton EW, et al. (2013) Recommendations for returning genomic incidental findings? We need to talk! Genet Med.
76. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, et al. (2013) ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15: 565-574.
77. Plon SE, Cooper HP, Parks B, Dhar SU, Kelly PA, et al. (2011) Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med 13: 148-154.
78. Bansal V, Libiger O, Torkamani A, Schork NJ (2010) Statistical analysis strategies for association studies involving rare variants. Nat Rev Genet 11: 773-785.
79. Hayden EC (2013) Geneticists push for global data-sharing. Nature 498: 16-17.
80. Koboldt DC, Ding L, Mardis ER, Wilson RK (2010) Challenges of sequencing human genomes. Brief Bioinform 11: 484-498.
81. Rosenfeld JA, Mason CE, Smith TM (2012) Limitations of the human reference genome for personalized genomics. PLoS One 7: e40294.
82. Trainor KJ, Wigmore DJ, Chrysostomou A, Dempsey JL, Seshadri R, et al. (1984) Mutation frequency in human lymphocytes increases with age. Mech Ageing Dev 27: 83-86.
83. O'Rawe J, Jiang T, Sun G, Wu Y, Wang W, et al. (2013) Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing. Genome Med 5: 28.
84. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.